Month: May 2023

LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official Cash, cash equivalents and marketable securities of $286.5 million with runway through the end of 2024SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the first quarter ended March 31, 2023. “We continue to achieve multiple significant milestones,...

NeuBase Reports Business Update and Financial Results for the First Quarter of 2023

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 PITTSBURGH, May 11, 2023 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments. “To date in 2023, we have made steady progress advancing the development of our gene editing application based on our PATrOL™ platform. One of the main drivers behind the initial success of this application...

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 data Initiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonist Reiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 millionSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter...

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first several months of 2023, we continued making progress to align with the FDA on an efficient development pathway to support registration of TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes and we remain on-track to commence study activities in the second half of the year,” said Paul Sekhri, Chief Executive Officer of vTv. “In addition to our ongoing efforts to advance studies of TTP399 in type 1 diabetes,...

Pineapple Energy Reports First Quarter 2023 Financial Results

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Revenue up 28% from Q4 2022 Gross profit up 60% from Q4 2022 Positive adjusted EBITDA and cash flow from continuing operations $7.6 million of cash, restricted cash and investmentsMINNETONKA, Minn., May 11, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the first quarter ended March 31, 2023. Pineapple CEO Kyle Udseth commented, “The strength of our Q1 results – the first full quarter with SUNation in the fold – showcases the value of our acquisition strategy and demonstrates our ability to execute operationally in integrating our businesses and driving accelerated performance. We’re ahead of schedule on our organic growth initiatives, and more importantly we reached the critical...

Cemtrex Reports Second Quarter 2023 Financial Results

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Q2’23 Revenue Increased 37% to $16.1M with Positive Operating Income of $0.4M Gross Margin up 1360 Basis Points to 46% in Q2’23 Management to Host Conference Call Today at 5:00 p.m. ET Brooklyn, NY, May 11, 2023 (GLOBE NEWSWIRE) — Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its financial and operational results for the second quarter ended March 31, 2023. Key Second Quarter FY 2023 and Subsequent HighlightsRevenue for Q2’23 increased 37% to $16.1 million, compared to revenue of $11.7 million for Q2’22.Security segment revenues increased 47% to $9.9m in Q2’23 as border protection vertical drives new order volumes for Vicon.Gross margin up 1360 basis points to 46% in Q2’23 from 32% in the prior year quarter Operating income of $0.4 million for Q2’23 compared...

Abcourt Completes Acquisition of Pershimex by Merger

Written by Customer Service on May 11, 2023. Posted in Mergers And Acquisitions.

VAL D’OR, Quebec, May 11, 2023 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (TSX-V: ABI) (“Abcourt” or the “Corporation”) and Pershimex Resources Corporation (TSX-V: PRO) (“Pershimex”) are pleased to announce that Abcourt has completed the previously announced acquisition of all of the issued and outstanding common shares of Pershimex (the “Pershimex Shares”) by way of a three-cornered amalgamation (the “Amalgamation”) under the Canada Business Corporations Act. Pursuant to the Amalgamation, Abcourt acquired all of the issued and outstanding Pershimex Shares for a consideration (the “Exchange Ratio”) of 0.5712 of a common share of Abcourt (“Abcourt Shares”) for each outstanding Pershimex Share. Abcourt now owns 100% of the outstanding Pershimex Shares. On closing of the Amalgamation, Abcourt issued an aggregate of 79,294,373 Abcourt Shares...

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

VALENCIA, Calif. and MELBOURNE, Australia, May 11, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the first quarter March 31, 2023. Financial Highlights and Recent UpdatesCommercial revenue, which excludes BARDA revenue, of $10.5 million, a 40% increase compared to $7.4 million for the same period in 2022 Total revenue, which includes BARDA revenue, of $10.6 million, a 40% increase compared to $7.5 million for the same period in 2022 Gross profit margin was 84% compared to 76% in the same period in 2022 Expanded field sales organization from 30 to 69, towards our goal of 70 Automated disaggregation...

SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia > 6 months Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia on Track for Interim Analysis by Late 2023/Early 2024 NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended March 31, 2023. “We are pleased with the continued advancement of both our galinpepimut-S (GPS) and GFH009 clinical programs...

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Written by Customer Service on May 11, 2023. Posted in Earnings Releases And Operating Results.

Presented initial preclinical data from ETX-123, Eliem’s lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, United Kingdom, May 11, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We were excited to share our initial preclinical data from ETX-123, our lead candidate in the Kv7 program, during the first quarter,”...

Month: May 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals